Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Thymosin Alpha-1 and KPV — mechanism, dosing, side effects, legal status, and pricing.
Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus gland that plays a critical role in immune system regulation. It is approved in over 35 countries for treating hepatitis B and C and as an immune adjuvant, and is studied for cancer immunotherapy.
KPV is a naturally occurring anti-inflammatory tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It is studied for its potent anti-inflammatory effects in the gut and skin without the pigmentation effects of full alpha-MSH.
Thymosin Alpha-1
KPV
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
Approved in over 35 countries (marketed as Zadaxin) for hepatitis B and as an immune adjuvant. Clinical trials show improved immune responses in hepatitis, cancer immunotherapy, and vaccine adjuvancy. It gained renewed interest during COVID-19 for its ability to restore immune competence in lymphopenic patients.
Preclinical studies demonstrate significant anti-inflammatory effects in models of colitis, dermatitis, and systemic inflammation. Oral KPV has shown efficacy in reducing intestinal inflammation in IBD models. Human clinical data is limited but promising for inflammatory bowel conditions.
Thymosin Alpha-1 and KPV are both in the Immune category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.